RT Journal Article
SR Electronic
T1 A Very Flat Peak: Exponential growth phase of COVID-19 is mostly followed by a prolonged linear growth phase, not an immediate saturation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.07.20055772
DO 10.1101/2020.04.07.20055772
A1 Santosh Ansumali
A1 Meher K. Prakash
YR 2020
UL http://medrxiv.org/content/early/2020/04/11/2020.04.07.20055772.abstract
AB When actively taking measures to control an epidemic, an important indicator of success is crossing the ‘peak’ of daily new infections. The peak is a positive sign which marks the end of the exponential phase of infection spread and a transition into a phase that is a manageable. Most countries or provinces with similar but independent growth trajectories had taken drastic measures for containing the COVID-19 pandemic and are eagerly waiting to cross the peak. However, the data after many weeks of strict measures suggests that most provinces instead enter a phase where the infections are in a linear growth. While the transition out of an exponential phase is relieving, the roughly constant number of daily new infections differ widely, range from around 50 in Singapore to around 2000 just in Lombardy (Italy), and 7600 in Spain. The daily new infection rate of a region seems to depend heavily on the time point in the exponential evolution when the restrictive measures were adopted, rather than on the population of the region. It is not easy to point the critical source of these persistent infections. We attempt to interpret this data using a simple model of newer infections mediated by asymptomatic patients, which underscores the importance of actively identifying any potential leakages in the quarantine. Given the novelty of the virus, it is hard to predict too far into the future and one needs to be observant to see if a plan B is needed as a second round of interventions. So far, the peak achieved by most countries with the first round of intervention is extremely flat.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding has been receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be available on request